HK Stock Market Move | GENSCRIPT BIO (01548) is now up over 6%. CARVYKTI's fourth quarter trade sales net amount is approximately 3.34 billion US dollars.

09:39 23/01/2025

Kingsway Biotech (01548) is now up over 6%, as of the time of writing, it is up 6.25% to 10.88 Hong Kong dollars, with a turnover of 54,841.2 million Hong Kong dollars.

GENSCRIPT BIO (01548) has surged over 6%, as of press time, up 6.25% to HKD 10.88, with a turnover of HKD 54.812 million. On the news front, GENSCRIPT BIO announced that its subsidiary Legend Biotech generated a net trade sales of approximately USD 334 million for the fourth quarter ending in December, representing a 16.8% increase over the previous quarter, under the cooperation and licensing agreement with Janssen. In addition, an official from the National Healthcare Security Administration stated that the first version of the Category B medical insurance list will be released by 2025. CICC International pointed out that the Category B list may prioritize drugs that have passed formal reviews and expert evaluations in China but have not been included in the basic medical insurance list, such as CAR-T and ADC therapies. This could potentially open up payment opportunities for domestic innovative drugs.

Jiangsu Hengrui Pharmaceuticals (01276): Injection of \(derived\) single-antibody \(drug\) approved to conduct clinical trials.

Northbound funds | Northbound trading volume reached a net buying of 5.345 billion yuan, with Europe and America adding sanctions on Russian oil. Northbound trading also increased its position in CNOOC (00883) by nearly 1 billion Hong Kong dollars.

YAN PALACE (01497) spent 810,000 Hong Kong dollars to repurchase 100,000 shares on October 23rd.

Jiangsu Hengrui Pharmaceuticals (01276): Injection of \(derived\) single-antibody \(drug\) approved to conduct clinical trials.

YAN PALACE (01497) spent 810,000 Hong Kong dollars to repurchase 100,000 shares on October 23rd.